Junqin Liang†
Fengxia Hu†Maoli Dan
Yingbing SangKailibinuer AbulikemuQian WangYongzhen Hong
Xiaojing Kang*- Department of Dermatology and Venereology, People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Dermatologic Diseases, Xinjiang Key Laboratory of Dermatology Research (XJYS1707), Urumqi, China
by Liang J, Hu F, Dan M, Sang Y, Abulikemu K, Wang Q, Hong Y and Kang X (2022) Front. Immunol. 13:825312. doi: 10.3389/fimmu.2022.825312
The title of this article was erroneously given as: “Safety and Efficacy of Nemolizumab for Atopic Dermatitis with Pruritus: A systematic review and meta-regression analysis of randomized controlled trial”. The correct title of the article is “Safety and efficacy of nemolizumab for patients with pruritus: a systematic review and meta-regression analysis of randomized controlled trial”.
There was a mistake in Table 1 as published. There was no ClinicalTrial.com.cn registration number provided, and the description of the study population was incomplete. The corrected Table 1 appears below.
Table 1. Characteristics of the included studies.
There was a mistake in Table 2 as published. We omitted a subgroup analysis for patients with AD only; this has now been added to the second row after ‘Pruritus VAS”.
The corrected Table 2 appears below.
Table 2. Combined results of the subgroup analyses.
There were few textual/grammatical errors throughout the article as given below:
In the Abstract; the phrase “in treating patients with AD” has been corrected to: “in treating patients with pruritus”
In Section “1. Introduction Section, Paragraph Number: 3”; “pruritus” was incorrectly written as “AD”. The phrase now reads: “pruritus by assessing the amelioration of pruritus”.
In Section “2. Materials and Methods Section, 2.1 “Literature search” Sub-section, Paragraph Number: 1”; “and”, has been corrected to “or”. The phrase now reads: “atopic dermatitis or pruritus”.
In Section “Results Section, 3.2 “Characteristics of the studies”, Paragraph Number: 1”; there was a lack of the explanation of the two no-AD studies. This has been added now and it reads: “Two of the included studies did not involve AD patients, one focused on individuals with prurigo nodularis (Ständer, S., et al., 2020), and the other on hemodialysis (Kinugasa, E., 2021).”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pruritus, atopic dermatitis (AD), nemolizumab, randomized controlled trial, meta-analysis
Citation: Liang J, Hu F, Dan M, Sang Y, Abulikemu K, Wang Q, Hong Y and Kang X (2026) Correction: Safety and efficacy of nemolizumab for patients with pruritus: a systematic review and meta-regression analysis of randomized controlled trial. Front. Immunol. 17:1773876. doi: 10.3389/fimmu.2026.1773876
Received: 04 January 2026; Accepted: 16 January 2026;
Published: 03 February 2026.
Edited and reviewed by:
Ruano Juan, University of Cordoba, SpainCopyright © 2026 Liang, Hu, Dan, Sang, Abulikemu, Wang, Hong and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaojing Kang, a2FuZ3hpYW9qaW5nMTYzQDE2My5jb20=
†These authors have contributed equally to this work and share first authorship